Conversely, the absence of TRAIL or the activation of PP2A can reverse these effects and enhance lung function, suggesting that the E3 ubiquitin ligase MID1 may serve as a viable target for IPF treatment. The gene discussed is PRKN; the disease is idiopathic interstitial pneumonia.